Semaglutides: weighing up the risks
-
Balado 22 avril 2025 22 avril 2025
-
Amérique du Nord, Royaume-Uni et Europe
-
Réformes réglementaires
-
Assurance et réassurance
The first episode of our 2025 podcast series covers Semaglutides, a diabetes control drug that works by activating glucagon-like peptide-1 (GLP-1) receptors to suppress appetite.
Partner Neil Beresford is joined by:
- Rosehana Amin, Partner, London
- Kirsten Soto, Senior Associate, Los Angeles
- Richard Manstoff, Senior Associate, London
Together they explore the potential risks and lawsuits surrounding Semaglutides, including their side effects and possible implications for insurers.
Fin
